We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+39.37%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$191M
AUM Growth
+$41.4M
Cap. Flow
-$4.33M
Cap. Flow %
-2.27%
Top 10 Hldgs %
52.91%
Holding
54
New
5
Increased
14
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.3M
2
LOXO
Loxo Oncology, Inc
LOXO
+$2.88M
3
PRTA icon
Prothena Corp
PRTA
+$2.68M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.96M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$1.47M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$2.97M
2
INDP icon
Indaptus Therapeutics
INDP
+$2.64M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$2.62M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.55M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 92.98%
2 Miscellaneous 7.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$23.3M 12.2%
785,000
+535,000
+214% +$13.3M
AXGN icon
2
Axogen
AXGN
$2.78B
$18.1M 9.45%
2,000,000
-120,000
-6% -$976K
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$14.3M 7.49%
1,045,000
-205,000
-16% -$2.06M
GNMX
4
DELISTED
Aevi Genomic Medicine Inc
GNMX
$10M 5.25%
1,800,000
-150,000
-8% -$855K
AGIO icon
5
Agios Pharmaceuticals
AGIO
$2.05B
$6.87M 3.59%
130,000
+45,000
+53% +$1.96M
KYNB
6
Kyntra Bio
KYNB
$32.4M
$6.83M 3.57%
13,200
– –
FOMX
7
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.83M 3.05%
630,000
-65,000
-9% -$543K
TVRD
8
Tvardi Therapeutics
TVRD
$24M
$5.64M 2.95%
18,750
-4,444
-19% -$963K
CDXS icon
9
Codexis
CDXS
$182M
$5.2M 2.72%
1,170,000
-8,500
-0.7% -$35.7K
CYNA
10
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$5.03M 2.63%
125,000
– –
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.99M 2.61%
275,000
+75,000
+38% +$1.47M
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.9M 2.56%
70,000
+20,000
+40% +$1.11M
HROW icon
13
Harrow
HROW
$1.44B
$4.63M 2.42%
1,215,381
-52,119
-4% -$203K
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.61M 2.41%
200,000
+48,000
+32% +$915K
MGNX icon
15
MacroGenics
MGNX
$260M
$4.34M 2.27%
145,000
+33,000
+29% +$982K
CMRX
16
DELISTED
Chimerix, Inc.
CMRX
$4.32M 2.26%
780,000
+105,000
+16% +$481K
NGNE icon
17
Neurogene
NGNE
$758M
$4.14M 2.17%
15,500
+750
+5% +$151K
ADMS
18
DELISTED
Adamas Pharmaceuticals
ADMS
$4.1M 2.15%
250,000
-50,000
-17% -$760K
IMMU
19
DELISTED
Immunomedics Inc
IMMU
$3.9M 2.04%
1,200,000
-100,000
-8% -$280K
XENE icon
20
Xenon Pharmaceuticals
XENE
$6B
$3.32M 1.74%
410,000
– –
PRTA icon
21
Prothena Corp
PRTA
$467M
$3M 1.57%
+50,000
New +$2.68M
PDSB icon
22
PDS Biotechnology
PDSB
$12.2M
$2.92M 1.53%
14,000
+2,720
+24% +$539K
LOXO
23
DELISTED
Loxo Oncology, Inc
LOXO
$2.88M 1.51%
+110,000
New +$2.88M
TRIL
24
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.59M 1.35%
175,000
-20,000
-10% -$230K
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
$2.52M 1.32%
220,000
-20,000
-8% -$185K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opaleye Management held 54 positions worth $191M, up 28% from $150M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Opaleye Management's Q3 2016 filing shows 5 new, 14 increased, 20 reduced and 9 closed positions. Its largest new stake was Loxo Oncology, Inc: 110,000 shares worth $2.88M. The largest sale was Amarin Corp, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2016 buy was Loxo Oncology, Inc: 110,000 shares worth $2.88M.
  • Opaleye Management added most to Blueprint Medicines in Q3 2016, an estimated $13.3M increase.
  • Opaleye Management's biggest Q3 2016 reduction was Amarin Corp, cutting an estimated $2.97M.
  • Opaleye Management fully exited Supernus Pharmaceuticals in Q3 2016, selling an estimated $2.55M.
  • Opaleye Management's ten largest holdings make up 53% of its $191M portfolio in Q3 2016.
  • Opaleye Management opened 5 new positions and closed 9 in Q3 2016.
  • Opaleye Management's portfolio value rose 28% quarter-over-quarter to $191M.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.